KAIMRC’S Second Therapeutics Discovery Conference

Proceedings

Mo Li¹  Yosra Boudjelal²  Sheraz Gul³  Theam Soon Lim⁴  Zeyad Alehaideb⁵  Jahad Alghamdi⁵  Mohammed Alassiri⁵  Ibrahim Bushnak⁵  Lamis Mouyes⁵  Bandar Alghanem⁵  Ahmed Alaskar⁵  Tlili Barhoumi⁵  Nimer Mehyar⁵  Ahmed Bakillah⁵  Salam Massadeh⁵  Mohamed Boudjelal⁵  Majid Alfadhel⁵  Bader Al Debasi⁵  Barrak Al Somaie⁵  Atef Nehdi⁵  Manal Alaamery⁵  Bahauddeen M. Alrfaei⁵  Imadul Islam⁵  Mai Al Ajaji⁵  Wyatt Yue⁶  Adel Nefzi⁷ 

[1] Biological and Environmental Science and Engineering Division, King Abdullah University of Science and Technology, Thuwal 23955-690, Saudi Arabia;College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia;Fraunhofer Institute for Molecular Biology and Applied Ecology IME - ScreeningPort, 22525 Hamburg, Germany;Institute for Research in Molecular Medicine, Universiti Sains Malaysia, Penang 11800, Malaysia;King Abdullah International Medical Research Centre, King Saud bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh 14611, Saudi Arabia;Structural Genomics Consortium, Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7BN, UK;Torrey Pines Institute for Molecular Studies, Port Saint Lucie, FL 34987-2352, USA;

关键词: drug discovery and development;    academic drug discovery;    rare diseases;    coronavirus;    infectious diseases;    KAIMRC;   

DOI  :  10.3390/proceedings2020043006

来源: DOAJ

【 摘 要 】

Following the success of our first therapeutic discovery conference in 2017 and the selection of King Abdullah International Medical Research Centre (KAIMRC) as the first Phase 1 clinical site in the Kingdom of Saudi Arabia, we organized our second conference in partnership with leading institutions in academic drug discovery, which included the Structural Genomic Constorium (Oxford, UK), Fraunhofer (Germany) and Institute Material Medica (China); the participation of members of the American Drug Discovery Consterium; European Biotech companies; and local pharma companies, SIPMACO and SudairPharma. In addition, we had European and Northern American venture capital experts attending and presenting at the conference. The purpose of the conference was to bridge the gap between biotech, pharma and academia regarding drug discovery and development. Its aim primarily was to: (a) bring together world experts on academic drug discovery to discuss and propose new approaches to discover and develop new therapies; (b) establish a permanent platform for scientific exchange between academia and the biotech and pharmaceutical industries; (c) entice national and international investors to consider funding drugs discovered in academia; (d) educate the population about the causes of diseases, approaches to prevent them from happening and their cure; (e) attract talent to consider the drug discovery track for their studies and career. During the conference, we discussed the unique academic drug discovery disrupting business models, which can make their discoveries easily accessible in an open source mode. This unique model accelerates the dissemination of knowledge to all world scientists to guide them in their research. This model is aimed at bringing effective and affordable medicine to all mankind in a very short time. Moreover, the program discussed rare disease targets, orphan drug discovery, immunotherapy discovery and process, the role of bioinformatics in drug discovery, anti-infective drug discovery in the era of bad bugs, natural products as a source of novel drugs and innovative drug formulation and delivery. Additionally, as the conference was organized during the surge of the epidemic, we dedicated the first day (25 February) to coronavirus science, detection and therapy. The day was co-organized with the King Saud bin Abdulaziz University for Health Sciences, Kingdom of Saudi Arabia(KSA) Ministry of Education to announce the grant winner for infectious diseases. Simultaneously, intensive courses were delivered to junior scientists on the principle of drug discovery, immunology and clinical trials, as well as rare diseases. The second therapeutics discovery forum provided a platform for interactive knowledge sharing and the convergence of researchers, governments, pharmaceuticals, biopharmaceuticals, hospitals and non-profit organizations on the topic of academic drug discovery. The event presented showcases on global drug discovery initiatives and demonstrated how collaborations are leading to successful new therapies. In line with the KSA 2030 vision on becoming world leaders with an innovative economy and healthy population, therapeutic discovery is becoming an area of interest to science leaders in the kingdom, and our conference gave us the opportunity to identity key areas of interest as well as potential future collaborations.

【 授权许可】

Unknown